Recent Research Progress of Extramedullary Plasmacytoma --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 607-611, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-982104
ABSTRACT
Extramedullary plasma cell tumor (EMP) is a kind of plasma cell tumor, and its pathogenesis is not completely clear. According to whether it is independent of myeloma disease, it can be divided into primary and secondary EMP, which have different biological and clinical characteristics. Primary EMP has low invasion, fewer cytogenetic and molecular genetic abnormalities and good prognosis, and surgery and / or radiotherapy are the mainly treatments. Secondary EMP, as the extramedullary invasive progression of multiple myeloma (MM), is often accompanied by high-risk cellular and molecular genetic abnormalities and poor prognosis, chemotherapy, immunotherapy and hematopoietic stem cell transplantation are the mainly treatment. This paper reviews the latest research progress of EMP in the pathogenesis, cytogenetics molecular genetics and treatment, so as to provide reference for clinical work.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Plasmacitoma
/
Pronóstico
/
Trasplante de Células Madre Hematopoyéticas
/
Mieloma Múltiple
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS